URMC / Labs / Ritchlin Lab / Publications

Publications

View All Publications

1. Norton H
2. Sliwinska-Stanczyk P
3. Hala T
4. El-Zorkany B
5. Stockert L
6. Mundayat R
7. Wang L
8. Ritchlin CT
Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.; Rheumatology and therapy. 2024 Dec 05.
1. Deane KD
2. Donlin LT
3. Ritchlin CT
4. Kuhn KA
Are There Disease Endotypes in Axial Spondyloarthritis and How Would We Define Them?; The Journal of rheumatology. 2024 Oct 24.
1. Mease PJ
2. Merola JF
3. Tanaka Y
4. Gossec L
5. McInnes IB
6. Ritchlin CT
7. Landewé RBM
8. Asahina A
9. Ink B
10. Heinrichs A
11. Bajracharya R
12. Shende V
13. Coarse J
14. Coates LC
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.; Rheumatology and therapy. 2024 Aug 31.
1. Bell RD
2. Brendel M
3. Konnaris MA
4. Xiang J
5. Otero M
6. Fontana MA
7. Bai Z
8. Krenitsky DM
9. Meednu N
10. Rangel-Moreno J
11. Scheel-Toellner D
12. Carr H
13. Nayar S
14. McMurray J
15. DiCarlo E
16. Anolik JH
17. Donlin LT
18. Orange DE
19. Kenney HM
20. Schwarz EM
21. Filer A
22. Ivashkiv LB
23. Wang F
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue.; Nature communications; Vol 15(1), pp. 7503. 2024 Aug 29.
1. Kenney HM
2. Chen KL
3. Schnur L
4. Fox JI
5. Wood RW
6. Xing L
7. Ritchlin CT
8. Rahimi H
9. Schwarz EM
10. Awad HA
High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy.; PloS one; Vol 19(7), pp. e0305623. 2024 Jul 05.
1. Ritchlin CT
2. Rangel-Moreno J
3. Martino D
4. Isett B
5. Paine A
6. Bhattacharya S
7. Fox J
8. Meyer EM
9. Bao R
10. Bruno T
11. Tausk F
12. de la Luz Garcia-Hernandez M
Psoriatic arthritis subtypes are phenocopied in humanized mice.; JCI insight; Vol 9(15). 2024 Jul 02.
1. Ritchlin CT
2. Mease PJ
3. Boehncke WH
4. Tesser J
5. Chakravarty SD
6. Rampakakis E
7. Shawi M
8. Schiopu E
9. Merola JF
10. McInnes IB
11. Deodhar A
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.; Clinical rheumatology. 2024 Jun 07.
1. Ogdie A
2. Merola JF
3. Mease PJ
4. Ritchlin CT
5. Scher JU
6. Lafferty KP
7. Chan D
8. Chakravarty SD
9. Langholff W
10. Wang Y
11. Choi O
12. Krol Y
13. Gottlieb AB
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.; BMC rheumatology; Vol 8(1), pp. 20. 2024 May 21.
1. Krueger JG
2. Eyerich K
3. Kuchroo VK
4. Ritchlin CT
5. Abreu MT
6. Elloso MM
7. Fourie A
8. Fakharzadeh S
9. Sherlock JP
10. Yang YW
11. Cua DJ
12. McInnes IB
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.; Frontiers in immunology; Vol 15, pp. 1331217. 2024 Apr 15.
1. Rahman P
2. McInnes IB
3. Deodhar A
4. Schett G
5. Mease PJ
6. Shawi M
7. Cua DJ
8. Sherlock JP
9. Kollmeier AP
10. Xu XL
11. Sheng S
12. Ritchlin CT
13. McGonagle D
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.; Clinical rheumatology. 2024 Mar 12.
1. Coates LC
2. Landewé R
3. McInnes IB
4. Mease PJ
5. Ritchlin CT
6. Tanaka Y
7. Asahina A
8. Behrens F
9. Gladman DD
10. Gossec L
11. Orbai AM
12. Gottlieb AB
13. Warren RB
14. Ink B
15. Bajracharya R
16. Shende V
17. Coarse J
18. Merola JF
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.; RMD open; Vol 10(1). 2024 Feb 22.
1. Chat VS
2. Ellebrecht CT
3. Kingston P
4. Bell S
5. Gondo G
6. Cordoro KM
7. Desai SR
8. Duffin KC
9. Feldman SR
10. Garg A
11. Gelfand JM
12. Gladman D
13. Green LJ
14. Gudjonsson J
15. Han G
16. Hawkes JE
17. Kircik L
18. Koo J
19. Langley R
20. Lebwohl M
21. Michael Lewitt G
22. Liao W
23. Martin G
24. Orbai AM
25. Reddy SM
26. Richardson V
27. Ritchlin CT
28. Schwartzman S
29. Siegel EL
30. Van Voorhees AS
31. Wallace EB
32. Weinberg JM
33. Winthrop KL
34. Yamauchi P
35. Armstrong AW
Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation.; Journal of the American Academy of Dermatology. 2024 Feb 06.
1. Furuya H
2. Nguyen CT
3. Chan T
4. Marusina AI
5. Merleev AA
6. Garcia-Hernandez ML
7. Hsieh SL
8. Tsokos GC
9. Ritchlin CT
10. Tagkopoulos I
11. Maverakis E
12. Adamopoulos IE
IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis.; Journal of autoimmunity; Vol 143, pp. 103167. 2024 Jan 31.
1. Ritchlin CT
2. Coates LC
3. McInnes IB
4. Mease PJ
5. Merola JF
6. Tanaka Y
7. Asahina A
8. Gossec L
9. Gottlieb AB
10. Warren RB
11. Ink B
12. Bajracharya R
13. Shende V
14. Coarse J
15. Landewé RB
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.; Annals of the rheumatic diseases. 2023 Sep 11.
1. Kenney HM
2. Rangel-Moreno J
3. Peng Y
4. Chen KL
5. Bruno J
6. Embong A
7. Pritchett E
8. Fox JI
9. Becerril-Villanueva E
10. Gamboa-Domínguez A
11. Quataert S
12. Muthukrishnan G
13. Wood RW
14. Korman BD
15. Anolik JH
16. Xing L
17. Ritchlin CT
18. Schwarz EM
19. Wu CL
Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis.; Frontiers in immunology; Vol 14, pp. 1237498. 2023 Aug 25.
1. Siebert S
2. Sweet KM
3. Ritchlin CT
4. Hsia EC
5. Kollmeier AP
6. Xu XL
7. Seridi L
8. Song Q
9. Gao S
10. Chen W
11. Miron M
Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.; ACR open rheumatology. 2023 Aug 08.
1. Bawany F
2. Ryan Wolff J
3. Ritchlin CT
4. Tausk F
Home Phototherapy Improves Access to Dermatologic Care: A Novel Stakeholder Alliance to Facilitate Its Implementation.; Clinical, cosmetic and investigational dermatology; Vol 16, pp. 1175-1180. 2023 May 02.
1. Leung YY
2. Kavanaugh A
3. Ritchlin CT
Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Anti-TNF inhibitor.; Arthritis & rheumatology (Hoboken, N.J.). 2023 Mar 16.
1. McGonagle D
2. McInnes IB
3. Deodhar A
4. Schett G
5. Shawi M
6. Chakravarty SD
7. Kollmeier AP
8. Xu XL
9. Sheng S
10. Xu S
11. Ritchlin CT
12. Rahman P
13. Mease PJ
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.; ACR open rheumatology. 2023 Mar 07.
1. Kenney HM
2. Dieudonne G
3. Yee S
4. Maki JH
5. Wood RW
6. Schwarz EM
7. Ritchlin CT
8. Rahimi H
Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands.; Lymphatic research and biology. 2023 Feb 20.
1. Ritchlin CT
2. Deodhar A
3. Boehncke WH
4. Soriano ER
5. Kollmeier AP
6. Xu XL
7. Zazzetti F
8. Shawi M
9. Jiang Y
10. Sheng S
11. Helliwell PS
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.; ACR open rheumatology. 2023 Feb 10.
1. Kenney HM
2. Wood RW
3. Ramirez G
4. Bell RD
5. Chen KL
6. Schnur L
7. Rahimi H
8. Korman BD
9. Xing L
10. Ritchlin CT
11. Schwarz EM
12. Cole CL
Implementation of automated behavior metrics to evaluate voluntary wheel running effects on inflammatory-erosive arthritis and interstitial lung disease in TNF-Tg mice.; Arthritis research & therapy; Vol 25(1), pp. 17. 2023 Feb 02.
1. Kenney HM
2. Peng Y
3. de Mesy Bentley KL
4. Xing L
5. Ritchlin CT
6. Schwarz EM
The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?; Current rheumatology reviews. 2023 Jan 27.
1. Peng Y
2. Kenney HM
3. de Mesy Bentley KL
4. Xing L
5. Ritchlin CT
6. Schwarz EM
Distinct mast cell subpopulations within and around lymphatic vessels regulate lymph flow and progression of inflammatory-erosive arthritis in TNF-transgenic mice.; Frontiers in immunology; Vol 14, pp. 1275871. 2023 Jan 14.
1. Ritchlin CT
2. Coates LC
3. Mease PJ
4. van der Heijde D
5. Song J
6. Jiang Y
7. Shawi M
8. Kollmeier AP
9. Rahman P
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.; Trials; Vol 24(1), pp. 22. 2023 Jan 10.
1. Kenney HM
2. Peng Y
3. Bell RD
4. Wood RW
5. Xing L
6. Ritchlin CT
7. Schwarz EM
Persistent popliteal lymphatic muscle cell coverage defects despite amelioration of arthritis and recovery of popliteal lymphatic vessel function in TNF-Tg mice following anti-TNF therapy.; Scientific reports; Vol 12(1), pp. 12751. 2022 Jul 26.
1. Coates LC
2. McInnes IB
3. Merola JF
4. Warren RB
5. Kavanaugh A
6. Gottlieb AB
7. Gossec L
8. Assudani D
9. Bajracharya R
10. Coarse J
11. Ink B
12. Ritchlin CT
Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Jul 13.
1. Orbai AM
2. Coates LC
3. Deodhar A
4. Helliwell PS
5. Ritchlin CT
6. Leibowitz E
7. Kollmeier AP
8. Hsia EC
9. Xu XL
10. Sheng S
11. Jiang Y
12. Liu Y
13. Han C
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.; The patient. 2022 Jun 30.
1. Coates LC
2. Ritchlin CT
3. Gossec L
4. Helliwell PS
5. Rahman P
6. Kollmeier AP
7. Xu XL
8. Shawi M
9. Karyekar CS
10. Contré C
11. Noël W
12. Sheng S
13. Wang Y
14. Xu S
15. Mease PJ
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.; Rheumatology (Oxford, England). 2022 Jun 29.
1. Stober C
2. McInnes IB
3. Raychaudhuri S
4. Mease PJ
5. Pennington SR
6. Scher JU
7. Chandran V
8. Armstrong AW
9. de Wit M
10. Cauli A
11. Jadon DR
12. Löve TJ
13. Ogdie A
14. O'Sullivan D
15. van Mens LJJ
16. Ritchlin CT
17. FitzGerald O
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2022 Apr 01.
1. Rangel-Moreno J
2. Garcia-Hernandez ML
3. Owen T
4. Barnard J
5. Becerril-Villanueva E
6. Kashyap T
7. Argueta C
8. Gamboa-Dominguez A
9. Tamir S
10. Landesman Y
11. Goldman BI
12. Ritchlin CT
13. Anolik JH
Small molecule inhibitors of nuclear export ameliorate lupus by modulating plasma cell generation and survival.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Mar 25.
1. Kenney HM
2. Wu CL
3. Loiselle AE
4. Xing L
5. Ritchlin CT
6. Schwarz EM
Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.; Arthritis research & therapy; Vol 24(1). 2022 Mar 07.
1. Ritchlin CT
2. Mease PJ
3. Boehncke WH
4. Tesser J
5. Schiopu E
6. Chakravarty SD
7. Kollmeier AP
8. Xu XL
9. Shawi M
10. Jiang Y
11. Sheng S
12. Wang Y
13. Xu S
14. Merola JF
15. McInnes IB
16. Deodhar A
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.; RMD open; Vol 8(1). 2022 Mar.
1. Garcia-Hernandez ML
2. Rangel-Moreno J
3. Garcia-Castaneda M
4. Kenney HM
5. Paine A
6. Thullen M
7. Anandarajah AP
8. Schwarz EM
9. Dirksen RT
10. Ritchlin CT
Dendritic cell-specific transmembrane protein is required for synovitis and bone resorption in inflammatory arthritis.; Frontiers in immunology; Vol 13, pp. 1026574. 2022 Jan 07.
1. McInnes IB
2. Asahina A
3. Coates LC
4. Landewé R
5. Merola JF
6. Ritchlin CT
7. Tanaka Y
8. Gossec L
9. Gottlieb AB
10. Warren RB
11. Ink B
12. Assudani D
13. Bajracharya R
14. Shende V
15. Coarse J
16. Mease PJ
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).; Lancet (London, England). 2022 Jan 05.
1. Merola JF
2. Landewé R
3. McInnes IB
4. Mease PJ
5. Ritchlin CT
6. Tanaka Y
7. Asahina A
8. Behrens F
9. Gladman DD
10. Gossec L
11. Gottlieb AB
12. Thaçi D
13. Warren RB
14. Ink B
15. Assudani D
16. Bajracharya R
17. Shende V
18. Coarse J
19. Coates LC
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).; Lancet (London, England). 2022 Jan 05.
1. Gondo GC
2. Noe MH
3. Bell SJ
4. Ritchlin CT
Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.; Journal of psoriasis and psoriatic arthritis; Vol 7(1), pp. 17-23. 2021 Dec 10.
1. Pournara E
2. Kormaksson M
3. Nash P
4. Ritchlin CT
5. Kirkham BW
6. Ligozio G
7. Pricop L
8. Ogdie A
9. Coates LC
10. Schett G
11. McInnes IB
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.; RMD open; Vol 7(3). 2021 Nov.
1. Kolbinger F
2. Di Padova F
3. Deodhar A
4. Hawkes JE
5. Huppertz C
6. Kuiper T
7. McInnes IB
8. Ritchlin CT
9. Rosmarin D
10. Schett G
11. Carballido JM
12. Häusermann P
13. Calonder C
14. Vogel B
15. Rondeau JM
16. Bruin G
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.; Pharmacology & therapeutics. 2021 Jun 22.
1. Ritchlin CT
2. Armstrong A
3. Johnsson H
4. Mulder MLM
GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
1. Stober C
2. Jadon DR
3. Armstrong AW
4. Chandran V
5. de Wit M
6. Helliwell PS
7. Mease PJ
8. Ogdie A
9. O'Sullivan D
10. Pennington SR
11. Löve T
12. Cauli A
13. van Mens L
14. Waxman R
15. Scher JU
16. Barton A
17. Ritchlin CT
18. FitzGerald O
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
1. Ogdie A
2. Ritchlin CT
Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
1. Rahman P
2. Ritchlin CT
3. Helliwell PS
4. Boehncke WH
5. Mease PJ
6. Gottlieb AB
7. Kafka S
8. Kollmeier AP
9. Hsia EC
10. Xu XL
11. Shawi M
12. Sheng S
13. Agarwal P
14. Zhou B
15. Ramachandran P
16. Zhuang Y
17. McInnes IB
Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.; The Journal of rheumatology. 2021 May 01.
1. McGonagle D
2. McInnes IB
3. Deodhar A
4. Schett G
5. Shawi M
6. Kafka S
7. Karyekar CS
8. Kollmeier AP
9. Hsia EC
10. Xu XL
11. Sheng S
12. Agarwal P
13. Zhou B
14. Ritchlin CT
15. Rahman P
16. Mease PJ
Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.; Rheumatology (Oxford, England). 2021 Apr 06.
1. Ogdie A
2. Ritchlin CT
Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. 2021 Feb 15.
1. Stober C
2. Jadon DR
3. Armstrong AW
4. Chandran V
5. de Wit M
6. Helliwell PS
7. Mease P
8. Ogdie A
9. O'Sullivan D
10. Pennington SR
11. Löve T
12. Cauli A
13. van Mens L
14. Waxman R
15. Scher JU
16. Barton A
17. Ritchlin CT
18. FitzGerald O
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2021 Feb 15.
1. Ritchlin CT
2. Helliwell PS
3. Boehncke WH
4. Soriano ER
5. Hsia EC
6. Kollmeier AP
7. Chakravarty SD
8. Zazzetti F
9. Subramanian RA
10. Xu XL
11. Zuraw QC
12. Sheng S
13. Jiang Y
14. Agarwal P
15. Zhou B
16. Zhuang Y
17. Shawi M
18. Karyekar CS
19. Deodhar A
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.; RMD open; Vol 7(1). 2021 Feb.
1. Gelfand JM
2. Armstrong AW
3. Bell S
4. Anesi GL
5. Blauvelt A
6. Calabrese C
7. Dommasch ED
8. Feldman SR
9. Gladman D
10. Kircik L
11. Lebwohl M
12. Lo Re V
13. Martin G
14. Merola JF
15. Scher JU
16. Schwartzman S
17. Treat JR
18. Van Voorhees AS
19. Ellebrecht CT
20. Fenner J
21. Ocon A
22. Syed MN
23. Weinstein EJ
24. Gondo G
25. Heydon S
26. Koons S
27. Ritchlin CT
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.; Journal of the American Academy of Dermatology. 2021 Jan 07.
1. Scallan JP
2. Bouta EM
3. Rahimi H
4. Kenney HM
5. Ritchlin CT
6. Davis MJ
7. Schwarz EM
Ex vivo Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis.; Frontiers in physiology; Vol 12. 2021.
1. Kenney HM
2. Bell RD
3. Masters EA
4. Xing L
5. Ritchlin CT
6. Schwarz EM
Lineage tracing reveals evidence of a popliteal lymphatic muscle progenitor cell that is distinct from skeletal and vascular muscle progenitors.; Scientific reports; Vol 10(1). 2020 Oct 22.